Advisory Board

Jack E. Ansell, MD
Jack E. Ansell, MD is the former Michael S. Bruno, MD, Chairman of Medicine at Lenox Hill Hospital and current Professor of Medicine at New York University School of Medicine. Dr. Ansell is a clinical investigator with a principal focus on the clinical problems of thrombosis, antithrombotic therapy, and the application of new modes of delivering and monitoring anticoagulants. He has authored more than 200 publications and has been the lead author for over 10 years of the major authoritative consensus guidelines for antithrombotic therapy through the American College of Chest Physicians. He is a Master of the American College of Physicians. Dr. Ansell received his medical degree from the University of Virginia and completed his medical residency at Tufts New England Medical Center followed by a fellowship in Hematology at Boston University.
Harvey Cantor, MD
Harvey Cantor, MD is Chair, Department of Cancer Immunology & AIDS and Baruj Benacerraf Professor of Microbiology and Immunobiology, Harvard Medical School. Dr. Cantor joined the Dana Farber Cancer Institute and Harvard faculty in 1974; since 1997, he has chaired the Department of Cancer Immunology and AIDS. He directed the DF/HCC Program in Cancer Immunology. He engages in teaching/training within the Harvard Medical School Graduate Program in Immunology and directs NIH postdoctoral training programs in AIDS research and cancer immunology. Dr. Cantor trained at the National Institutes of Health and National Institute for Medical Research in London. He received an MD from New York University in 1967 and completed residency in medicine at Stanford. In 2002, Dr. Cantor was elected to the U.S. National Academy of Sciences.
S. Thomas Emerson, PhD
S. Thomas Emerson, PhD is David T. and Lindsay J. Morgenthaler Professor of Entrepreneurship at the Carnegie Mellon Tepper School of Business. Dr. Emerson is an experienced entrepreneur, corporate executive, and educator. He founded and built three venture capital backed high technology companies: Periphonics Corporation, Syntellect Inc., and Xantel Corporation. Two of these companies (Periphonics and Syntellect) became NASDAQ-listed national market companies. They created in aggregate more than $600 million in shareholder value. Dr. Emerson was named Inventor of the Year by the U.S. Patent Office in 1973. Prior to joining Carnegie Mellon, he was President and CEO of Arizona Technology Incubator, a public-private partnership in Scottsdale, Arizona that mentors promising young technology companies.